CONTACT US
TREATMENT CENTERS
HEAD/NECK CANCER

A precise, accurate and convenient treatment solution for prostate cancer

You have more options than ever for successfully treating prostate cancer. The “best” option for you is the one that fits your life — from the specifics of your cancer and your overall health, to your age and lifestyle. The CyberKnife® System was designed to help you gain control over your prostate cancer in the shortest number of physician visits and with as little impact on your romantic life or urinary and bowel function as possible. The result? You get back to a healthy, full life, faster.

Key CyberKnife® treatment benefits

  • Excellent long-term cancer control
  • Significantly reduced incidence of sexual, urinary and bowel function side effects
  • Non-surgical and non-invasive
  • Treatments completed in as little as 4-5 visits across 1-2 weeks
  • Most patients can continue normal activity throughout treatment

Ask a physician if CyberKnife treatment is right for you

You deserve the best possible treatment for your prostate cancer. Find a physician in your area offering the CyberKnife System — and find out if CyberKnife treatment is right for you.

Find a Treatment Center

A non-invasive, non-surgical option with proven results

The CyberKnife System is a non-invasive, non-surgical, pain-free treatment option for prostate cancer with proven results. It is the first and only radiotherapy device that brings true robotic precision and the ability to track, detect and correct for tumor motion in real-time, to the treatment of cancer. These capabilities enable your medical team to deliver radiation with sub-millimeter accuracy, helping to minimize the risk of side effects and preserve your quality of life during and after treatment. The CyberKnife technology is not new; the system has more than a decade of clinical evidence and has helped thousands of men with prostate cancer.

Read the Clinical Proof

More than two decades of clinical proof

The CyberKnife is commonly used for treating low- to intermediate-risk prostate cancer and is the only radiotherapy device supported by years of published clinical follow-up with a large number of patients.

SAFE AND EFFECTIVE

Prospective, multi-institutional study data supports the safety and efficacy of CyberKnife for men with low- and intermediate-risk prostate cancer.1, 2

EXCELLENT LONG-TERM OUTCOMES

Clinical studies report CyberKnife provides excellent long-term disease control for prostate patients.3, 4, 5, 6, 7, 8, 9

20,000+ PROSTATE CANCER TREATMENTS

More than 20,000 men have been treated with CyberKnife.

References:

1 Meier. R. et al. “Five-Year Outcome From a Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer.” International Journal of Radiation Oncology • Biology • Physics, Volume 96, Issue 2, S33 – S34.

2 Fuller D.B., et. al. “5-year outcomes from a prospective multi-institutional trial of heterogeneous dosing stereotactic body radiotherapy (SBRT) for low- and intermediate-risk prostate cancer.” J Clin Oncol 35. 2017; 6S;35.

3 Zelefsky M.J., Chan H et al. “Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.” J Urol 2006; 176:1415-9.

4 Cheung R., Tucker S.L. et al. “Dose-Response Characteristics of Low- and Intermediate-Risk Prostate Cancer Treated with External Beam Radiotherapy.” Int J Radiat Oncol Biol Phys 2005; 61(4): 993-1002.

5 Lawton CA, DeSilvio M, Lee WR, et al. “Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05).” Int J Radiat Oncol Biol Phys 67:39-47, 2007.

6 Taira AV, Merrick GS, Galbreath RW, et al. “Natural history of clinically staged low-and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.” Int J Radiat Oncol Biol Phys 76:349-54, 2010.

7 Demanes D. J. et al. “High dose rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer.” Int J Radiat Oncol Biol Phys 81(5): 1286-1292, 2011.

8 Michalski JM, Moughan J, Purdy J, et al. “A randomized trial of 79.2 Gy versus 70.2 Gy radiation therapy (RT) for localized prostate cancer.” J Clin Oncol 33(S7): abstr4, 2015.

9 Spratt DE, Pei X, Yamada J, et al. “Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer.” Int J Radiat Oncol Biol Phys 85:686–92, 2013

The prostate moves. The CyberKnife System adapts and synchronizes treatment delivery with the motion in real time.

The prostate gland can move unpredictably throughout the course of treatment — as much as half an inch in as little as 30 seconds because of normal patient bodily functions (filling of the bladder, gas in the bowel, or even slight patient movement).1 Unlike any other radiation treatment, the CyberKnife System continually tracks the target, automatically adapts and synchronizes the radiation beam with movement of the prostate in real-time throughout the entire treatment session. This helps to ensure the radiation dose is delivered to the target — maximizing treatment effectiveness while protecting surrounding tissues to reduce the incidence of side effects.

Sub-millimeter robotic precision

The CyberKnife robot, guided by motion synchronization software, can deliver radiation from virtually any angle — allowing it to maintain sub-millimeter accuracy throughout treatment delivery. Greater precision helps minimize dose to surrounding healthy tissues, reducing the risk of many common side effects.1, 2, 3, 4

References:

1 Yu, C., Main, W., Taylor, D., Kuduvalli, G., Apuzzo, M. L., Adler. J.R. Jr. “An anthropomorphic phantom study of the accuracy of CyberKnife spinal radiosurgery.” Neurosurgery. 2004 55(5):1138-49.

2 Antypas C. and Pantelis E. “Performance evaluation of a CyberKnife G4
image-guided robotic stereotactic radiosurgery system.” Phys Med Biol
2008;53:4697-4718.

3 Drexler and Furweger. Quality assurance of a robotic, image guided radiosurgery system. WC 2009, IFMBE Proceedings 25/I, 492-495, 2009.

4 Kilby. W. et al. The CyberKnife Robotic Radiosurgery system in 2010. TCRT 2010;9(5):433-452

CyberKnife patient satisfaction data1

OF PATIENTS
0 %

would choose CyberKnife treatment again

OF PATIENTS
0 %

report CyberKnife treatment did not interrupt their normal life routine

OF PATIENTS
0 %

would recommend CyberKnife treatment to others

References:

1 CyberKnife Coalition patient survey: 304 patients that received SBRT to treat prostate cancer. 2010

Enables re-treatment after previous radiation

Because the precise targeting of the CyberKnife System significantly reduces irradiation of surrounding healthy tissues, CyberKnife can be a powerful treatment option for a wider range of prostate cancer patients:

  • CyberKnife may provide a safe radiation treatment option even for patients who have previously received radiation therapy.
  • Patients treated with CyberKnife are excellent candidates for re-treatment, in the event of recurrence.
  • Patients treated with CyberKnife may still be candidates for surgical interventions, in the event of recurrence.

CyberKnife® vs. traditional treatments

An effective, less disruptive
re-treatment option

The unparalleled precision and motion synchronization capabilities of the CyberKnife System maximize radiation delivered to the target — while helping to safeguard surrounding healthy tissues. The result is highly effective treatment that eliminates many of the inconveniences of other treatments — and significantly reduces the risk of the side effects that too often disrupt the lives of patients during and after treatment.

CYBERKNIFE VS. SURGERY

CyberKnife treatment is an outpatient procedure that does not require incisions or general anesthesia. Most patients will not require hospitalization or a long recovery period.

CYBERKNIFE VS. BRACHYTHERAPY

CyberKnife treatment eliminates the inconvenience and risk associated with radioactive seed or catheter implants.

CYBERKNIFE VS. CONVENTIONAL RADIATION THERAPY

CyberKnife treatment is completed in as little as 4-5 sessions over 1-2 weeks, compared to 30-40 sessions over 8-10 weeks with conventional radiation therapy.

Find a CyberKnife Treatment Center

View All Patient Stories

Learn More About CyberKnife Treatment

References:

1 Meier. R. et al. Five-Year Outcome From a Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer. http://dx.doi.org/10.1016/j.ijrobp.2016.06.094

Fuller D.B., et. al. 5-year outcomes from a prospective multi-institutional trial of heterogeneous dosing stereotactic body radiotherapy (SBRT) for low- and intermediate-risk prostate cancer. J Clin Oncol 35. 2017; 6S;35

2 Zelefsky M.J., Chan H et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006; 176:1415-9.

Cheung R., Tucker S.L. et al. Dose-Response Characteristics of Low- and Intermediate-Risk Prostate Cancer Treated with External Beam Radiotherapy. Int J Radiat Oncol Biol Phys 2005; 61(4): 993-1002.

Lawton CA, DeSilvio M, Lee WR, et al. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). Int J Radiat Oncol Biol Phys 67:39-47, 2007.

Taira AV, Merrick GS, Galbreath RW, et al. Natural history of clinically staged low-and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 76:349-54, 2010.

Demanes D. J. et al. High dose rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 81(5): 1286-1292, 2011.

Michalski JM, Moughan J, Purdy J, et al. A randomized trial of 79.2 Gy versus 70.2 Gy radiation therapy (RT) for localized prostate cancer. J Clin Oncol 33(S7): abstr4, 2015.

Spratt DE, Pei X, Yamada J, et al. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 85:686–92, 2013.

3 Yu, C., Main, W., Taylor, D., Kuduvalli, G., Apuzzo, M. L., Adler. J.R. Jr. An anthropomorphic phantom study of the accuracy of CyberKnife spinal radiosurgery. Neurosurgery. 2004 55(5):1138-49.

Antypas C. and Pantelis E. Performance evaluation of a CyberKnife G4
image-guided robotic stereotactic radiosurgery system. Phys Med Biol
2008;53:4697-4718

Drexler and Furweger. Quality assurance of a robotic, image guided radiosurgery system. WC 2009, IFMBE Proceedings 25/I, 492-495, 2009

Kilby. W. et al. The CyberKnife Robotic Radiosurgery system in 2010. TCRT 2010;9(5):433-452

4  CyberKnife Coalition patient survey: 304 patients that received SBRT to treat prostate cancer. 2010

© 2024 Accuray Incorporated. All rights reserved.

Share Your Story

Educating others about your experience with the CyberKnife® System can help others who face similar decisions about their own cancer treatment choices.

If you are interested in sharing your story, please fill out the form below and an Accuray representative will contact you.

Please note: Accuray is the manufacturer of the CyberKnife®, TomoTherapy®, and Radixact® Systems. As the manufacturer, we are unable to provide specific medical advice, view medical records, or schedule appointments.
Privacy Disclaimer: To protect your safety, please do not provide your personal or sensitive information, such as your medical history, on our websites. By entering any information on our websites, you understand and agree that such information will be transferred to Accuray Incorporated in the United States. Please read our Privacy Policy.
Important Safety Statement: Most side effects of radiotherapy, including radiotherapy delivered with Accuray systems, are mild and temporary, often involving fatigue, nausea, and skin irritation. Side effects can be severe, however, leading to pain, alterations in normal body functions (for example, urinary or salivary function), deterioration of quality of life, permanent injury and even death. Side effects can occur during or shortly after radiation treatment or in the months and years following radiation. The nature and severity of side effects depend on many factors, including the size and location of the treated tumor, the treatment technique (for example, the radiation dose), the patient’s general medical condition, to name a few. For more details about the side effects of your radiation therapy, and if treatment with an Accuray product is right for you, ask your doctor.